Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales
Apellis stock plunged Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations. The post Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales appeared first on Investor's Business Daily.
Apellis stock plunged Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations.
The post Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
